ExploreWatchlistsPricing
  1. US-listed companies
  2. Theravance Biopharma, Inc.
  3. Financials
  4. Cash from operations

Theravance Biopharma, Inc. (TBPH)

Market cap
$849.63M
P/E ratio
8x
SummaryFinancials
Period EndCash from operations (Million USD)YoY (%)
Dec 31, 2025239-2167.98%
Dec 31, 2024-12-57.27%
Dec 31, 2023-27+1013.28%
Dec 31, 2022-2-98.83%
Dec 31, 2021-208-16.99%
Dec 31, 2020-250+5.12%
Dec 31, 2019-238+111.04%
Dec 31, 2018-113-43.86%
Dec 31, 2017-201+103.11%
Dec 31, 2016-99-41.38%
Dec 31, 2015-169-3.60%
Dec 31, 2014-175

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat